Metabolic Targets in Nonalcoholic Fatty Liver Disease

The prevalence and diagnosis of nonalcoholic fatty liver disease (NAFLD) is on the rise worldwide and currently has no FDA-approved pharmacotherapy. The increase in disease burden of NAFLD and a more severe form of this progressive liver disease, nonalcoholic steatohepatitis (NASH), largely mirrors...

Descripción completa

Detalles Bibliográficos
Autores principales: Esler, William P., Bence, Kendra K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698700/
https://www.ncbi.nlm.nih.gov/pubmed/31004828
http://dx.doi.org/10.1016/j.jcmgh.2019.04.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698700/
https://www.ncbi.nlm.nih.gov/pubmed/31004828
http://dx.doi.org/10.1016/j.jcmgh.2019.04.007

Ejemplares similares